The agreement creates a working relationship between the parties for the manufacturing development and current good manufacturing practice (cGMP) manufacture of the company’s lead novel therapeutic drug liposomal Grb-2.
It is expected that the cGMP drug product manufactured by Althea will be used in the Phase I clinical study of liposomal Grb-2 in chronic myelogenous leukemia, and acute myeloid leukemia which Bio-Path plans to conduct at The University of Texas MD Anderson Cancer Center.
Magda Marquet, co-president and co-CEO of Althea, said: “We are very pleased to begin work on Bio-Path’s leading drug candidate. The Grb-2 therapeutic program is exciting in that it could potentially benefit patients with leukemia and provide a way forward for the delivery of nucleic acid therapeutics.”